Anemia Clinical Trial
Official title:
Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia
Iron affects immunity. However, the exact effect of iron on the innate immune response is not known. Animal data suggest that iron administration induced oxidative stress which enhances the innate immune response, whereas iron chelation has the opposite effect. The investigators tested the hypothesis that administration of iron sucrose 1.25 mg/kg augments the innate immune response, and iron chelation by deferasirox 30 mg/kg attenuates the innate immune response during human experimental endotoxemia.
Systemic inflammation is accompanied by profound changes in iron distribution, mainly under
the influence of hepcidin, leading to sequestration of iron in macrophages of the
reticuloendothelial system, and ultimately anemia of inflammation. This redistribution of
iron may represent an effective defense mechanism against a variety of pathogens, that need
iron for replication and growth. The fact that iron withholding strategy is such a highly
conserved part of the innate immune response illustrates that iron homeostasis and immunity
are closely related. Concordantly, several studies in animal models have revealed immune
modulatory effects of both iron and iron chelation: Iron sucrose has been shown to
potentiate the inflammatory response and associated mortality, while iron chelation appears
to attenuate inflammation and improve outcome in murine models of inflammation and sepsis.
The immune modulatory effects of iron supplements and chelators are mainly attributed to
their ability to potentiate or reduce the formation of reactive oxygen species (ROS). A
subfraction of non-transferrin bound catalytically active iron, labile plasma iron, is
thought to be responsible as this free iron is able to easily donate or accept electrons,
thereby fueling redox reactions. Oxidative stress is associated with propagation of the
immune response, endothelial dysfunction, and contributes to the organ damage that occurs
during systemic inflammation. In accordance, anti-oxidants exert anti-inflammatory effects.
As such, iron chelation has been suggested to be a valuable adjuvant therapy during
infection for two distinct reasons: inhibition of bacterial growth and protection of organs
against inflammation induced oxidative stress.
Effects of iron status on the immune response has up till now mainly been investigated in in
vitro and in animal models, often using supra-therapeutic dosages of iron donors or iron
chelators. Data on the effect of iron loading and iron chelation during systemic
inflammation in humans are lacking. The objectives of the present study were to investigate
the acute effect of therapeutic dosages of iron loading and iron chelation therapy on iron
homeostasis, oxidative stress, the innate immune response, and subclinical organ injury
during systemic inflammation induced by experimental endotoxemia in humans in vivo.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |